Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics.
Therapeutic targeting of tumours on the basis of molecular analysis is a new paradigm for cancer treatment but has yet to fulfil expectations. For many solid tumours, targeted therapeutics, such as inhibitors of oncogenic kinase pathways, elicit predominantly disease-stabilizing, cytostatic responses, rather than tumour regression. Combining oncogenic kinase inhibitors with direct activators of the apoptosis machinery, such as the BH3 mimetic ABT-737, may unlock potent anti-tumour potential to produce durable clinical responses with less collateral damage.
Cragg
Mark S
MS
The Walter and Eliza Hall Institute of Medical Research, Parkville, Melbourne, Victoria, Australia. msc@soton.ac.uk
Harris
Claire
C
Strasser
Andreas
A
Scott
Clare L
CL